Clinical trial
A Study to Evaluate the Long-term Efficacy and Safety of FXS6837 in IgAN Patients
NCT07750665 is registered in ClinicalTrials.gov with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study to Evaluate the Long-term Efficacy and Safety of FXS6837 in IgAN Patients
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- January 4, 2030
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
primary igan